CN102210763B - Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof - Google Patents
Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof Download PDFInfo
- Publication number
- CN102210763B CN102210763B CN2011101411337A CN201110141133A CN102210763B CN 102210763 B CN102210763 B CN 102210763B CN 2011101411337 A CN2011101411337 A CN 2011101411337A CN 201110141133 A CN201110141133 A CN 201110141133A CN 102210763 B CN102210763 B CN 102210763B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- promoting
- circulation
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000008280 blood Substances 0.000 title claims abstract description 11
- 210000004369 blood Anatomy 0.000 title claims abstract description 11
- 230000017531 blood circulation Effects 0.000 title claims abstract description 11
- 230000004087 circulation Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 27
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 239000008187 granular material Substances 0.000 claims abstract description 11
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 10
- 229940013618 stevioside Drugs 0.000 claims abstract description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- 229920001353 Dextrin Polymers 0.000 claims abstract description 9
- 239000004375 Dextrin Substances 0.000 claims abstract description 9
- 235000019425 dextrin Nutrition 0.000 claims abstract description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 4
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 4
- 241000219780 Pueraria Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 2
- 241001072909 Salvia Species 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000013558 reference substance Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 6
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000010365 xinkeshu Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- DFOATKRXQLALOL-UHFFFAOYSA-N 2-(2-hydroxyethyl)benzene-1,3,5-triol Chemical compound OCCC1=C(O)C=C(O)C=C1O DFOATKRXQLALOL-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and a preparation method thereof. The Chinese medicinal composition comprises the following components in part by weight: 7.5 to 22.5 parts of hawthorn fruit, 7.5 to 22.5 parts of root of red-rooted salvia, 7.5 to 22.5 parts of kudzuvine root, 1 to 3 parts of notoginseng root and 1 to 3 parts of costustoot. The preparation method for granules comprises the following steps of: crushing notoginseng root and costustoot to form 150 to 250-mesh fine powder by using a micro powder crusher for later use; crushing hawthorn fruit, root of red-rooted salvia and kudzuvine root for form coarse powder; extracting active ingredients from the coarse powder by using supercritical carbon dioxide fluid, after extracting, reducing system pressure to normal pressure, and precipitating and separating extracted substances to obtain extractum; and drying the extractum, crushing the extractum to form 150 to 250-mesh fine powder, mixing with the fine powder of notoginseng root and costustoot and proper amount of dextrin and stevioside uniformly to prepare granules, and packaging to obtain the Chinese medicinal composition. The preparation method has a simple production process, and is high in extraction speed, the active ingredients are easy to separate, the Chinese medicinal composition does not have residual toxicity, and is high in purity and good in curative effect, and structures and properties of active substances are not damaged.
Description
Technical field
The present invention relates to a kind of blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain Chinese medicine composition and preparation method thereof.
Background technology
" Chinese medicine ministry standard " the 15th records a kind of XINKESHU JIAONANG, and prescription is Fructus Crataegi, Radix Puerariae, Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Aucklandiae.Method for making: the above five tastes, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae added 60% ethanol warm macerating after 30 minutes, the heating and refluxing extraction secondary, and 2.5 hours for the first time, 2 hours for the second time, merge alcohol extract, decompression recycling ethanol is concentrated into relative density 1.35 (20 ℃); Radix Salviae Miltiorrhizae decocte with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filtered, and is concentrated into relative density 1.35 (20 ℃); Above-mentioned two kinds of thick pastes are dry under 80 ℃, be ground into fine powder and Radix Notoginseng, Radix Aucklandiae fine powder mixing, process granule, drying is distributed into 1000, promptly gets.
By on can know that existing preparation technology adopts alcohol extracting method or water extraction to Fructus Crataegi, Radix Puerariae, Radix Salviae Miltiorrhizae.Existing literature research data shows: the chemical constituent of Fructus Crataegi is organic acid, triterpenes, flavonoid and polysaccharide etc., and flavone and polysaccharide have blood pressure lowering, hypolipemic function preferably.Puerarin has another name called puerarin, is a kind of flavonoid glycoside that from the leguminous plant Radix Puerariae, extracts.Puerarin has arrhythmia, coronary artery dilator, protection myocardial ultrastructure, cerebral blood flow increasing amount, anticoagulant, effects such as antioxidation, enhancing human body immunity power and the formation of inhibition human skin melanin.Radix Salviae Miltiorrhizae is the most frequently used Chinese medicine of promoting blood circulation to restore menstrual flow, and known active component is for being the tanshinone liposoluble substance of representative with the tanshinone IIA and being the water-soluble substances of representative with salvianolic acid B, protocatechualdehyde that character to each other differs comparatively great disparity.
Research shows, adopts conventional water extraction, alcohol extracting method to extract the effective ingredient of Chinese crude drug, and effect is undesirable, and paste-forming rate is big, and is consuming time longer, and extraction efficiency is not high, the separation and purification difficulty, and effective ingredient purity is low.
Summary of the invention
The technical problem that the present invention will solve is, provides a kind of production technology simple and easy, and product purity is high, and the product non-residual toxicity does not damage blood circulation promoting and blood stasis dispelling promoting the circulation of QI to relieve pain Chinese medicine composition of active substance structure and character and preparation method thereof.
The technical scheme that the present invention solves its technical problem employing is:
The present invention's blood circulation promoting and blood stasis dispelling promoting the circulation of QI to relieve pain Chinese medicine composition is processed by following parts by weight of Chinese traditional medicine crude drug and adjuvant: Fructus Crataegi 7.5-22.5 part, Radix Salviae Miltiorrhizae 7.5-22.5 part, Radix Puerariae 7.5-22.5 part, Radix Notoginseng 1-3 part, Radix Aucklandiae 1-3 part, stevioside 0.25-0.75 part, dextrin 7.5-22.5 part.
Preferred weight proportion is: 15 parts of Fructus Crataegis, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Puerariaes, 2 parts of Radix Notoginseng, 2 parts of the Radix Aucklandiae, 0.5 part of stevioside, 15 parts in dextrin.
The method for preparing of the present invention's blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain Chinese medicinal composition granules may further comprise the steps: Radix Notoginseng, the Radix Aucklandiae are ground into 150-250 purpose fine powder with the micropowder pulverizer, and subsequent use; Fructus Crataegi, Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into 50-70 order (preferred 60 orders) powder, adopt its effective active composition of supercritical carbon dioxide extraction method extraction, the extraction process condition is following: extracting pressure 34-36MPa (preferred 35MPa); Extraction temperature 48-52 ℃ (preferred 50 ℃) extract time 110-130 minute (preferred 120 minutes), separator pressure 9.0-11.0MPa (preferred 10.0 MPa); Separator temperature 39-41 ℃ (preferred 40 ℃), carbon dioxide flow are 78-82L/H (preferred 80L/H), and extraction finishes; System pressure is reduced to normal pressure, and extract is separated out separation, gets extractum; With extract dry, be ground into 150-250 order fine powder then, with Radix Notoginseng, Radix Aucklandiae fine powder and dextrin, stevioside mixing; Process granule, packing.
Added the stevioside of tool hypotensive activity in the medicament composing prescription of the present invention, promptly improved the mouthfeel of preparation, be adapted to middle-older patient especially and take, but Synergistic treatment " three-hypers " symptom again, thus increase the product curative effect.Preparation technology of the present invention adopts supercritical carbon dioxide extraction technology, and it is simple and easy to have extraction process, and rate of extraction is fast, and the effective active composition is easy to separate, the product non-residual toxicity, and product purity is high, does not damage the advantages such as structure and character of active substance.
The specific embodiment
Below in conjunction with embodiment the present invention is described further.
Embodiment 1
Present embodiment composition weight proportioning: 15 parts of Fructus Crataegis, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Puerariaes, 2 parts of Radix Notoginseng, 2 parts of the Radix Aucklandiae, 15 parts in dextrin, 0.5 part of stevioside.
Preparation: get Radix Notoginseng, the Radix Aucklandiae and be ground into the 150-250 order with the micropowder pulverizer to get fine powder subsequent use; Fructus Crataegi, Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into 60 order powder, adopt its effective active composition of supercritical carbon dioxide extraction (extracting pressure 35MPa, 50 ℃ of extraction temperature, extraction time 2H; Separator pressure 10MPa, 40 ℃ of separator temperatures, carbon dioxide flow is 80L/H); Extraction finishes, and system pressure is reduced to normal pressure, and extract is separated out; Get extractum,, again extract powder is broken into 150-250 order fine powder then with extract dry; With Radix Notoginseng, Radix Aucklandiae fine powder and an amount of dextrin, stevioside mixing, process granule, packing promptly gets.
The method of inspection:
1 bag of these article are got in [discriminating] (1), porphyrize, and the 30ml that adds diethyl ether, supersound process (power 300W, frequency 25KHz) 15 minutes filters, and filtrating volatilizes, and residue adds methanol 1ml makes dissolving, as need testing solution.Other gets Radix Aucklandiae control medicinal material 1g, shines medical material solution in pairs with legal system.Get the ursolic acid reference substance again, add dehydrated alcohol and process the solution that every 1ml contains 1mg, as reference substance solution.According to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2010 B) test, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate; With cyclohexane extraction-chloroform-ethyl acetate-formic acid (20: 5: 8: 0.1) be developing solvent; Launch, take out, dry; Spray is with 10% ethanol solution of sulfuric acid, and it is clear that hot blast blows to the speckle colour developing.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show corresponding aubergine speckle; With the corresponding position of control medicinal material chromatograph on, show identical redness and blue two speckles.
(2) get 1 bag of these article, porphyrize adds methanol 20ml, and supersound process (power 300W, frequency 25KHz) 15 minutes filters, and filtrating is as need testing solution.Other gets the protocatechualdehyde reference substance, adds methanol and processes the solution that every 1ml contains 0.5mg, as reference substance solution.According to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2010 B) test, draw need testing solution 20 μ l, reference substance solution 5 μ l; Put respectively on same silica gel g thin-layer plate; With toluene-ethyl acetate-formic acid (8: 5: 0.5) is developing solvent, launches, and takes out; Dry, spray is with the mixed solution of 1% phloroglucinol ethanol liquid-sulphuric acid (1: 1).In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get 1 bag of these article, porphyrize takes by weighing 0.5g, the 10ml that adds diethyl ether, supersound process (power 300W; Frequency 25KHz) 5 minutes, filter, discard ether solution, residue volatilizes solvent, adds methanol 25ml; Reflux 15min is put coldly, filters, and the filtrating evaporate to dryness, residue adds water 25ml; Slight fever makes dissolving, and with the saturated n-butyl alcohol liquid 25ml of ammonia solution, jolting is extracted, and gets n-butanol extracting liquid, and the ammonia solution saturated with n-butyl alcohol washs 2 times; Each 25ml, evaporate to dryness butanol solution, residue add methanol 1ml makes dissolving, as need testing solution.Other gets Radix Notoginseng control medicinal material 0.1g, adds diethyl ether and shines medical material solution in pairs with legal system.Get ginsenoside Rg1's reference substance again, ginsenoside Rb1's reference substance and arasaponin R1 reference substance add methanol and process the mixed solution that every 1ml contains 0.5mg, as reference substance solution.Test according to thin layer chromatography (Chinese Pharmacopoeia version appendix in 2010 VI B); Drawing each 5 μ l of above-mentioned need testing solution, control medicinal material solution and reference substance solution, put respectively on same silica gel g thin-layer plate, is developing solvent with 10 ℃ of lower floor's solution with held of chloroform-methanol-water (13:7:2); Launch; Dry, spray is with 10% ethanol solution of sulfuric acid, and 105 ℃ to be heated to speckle colour developing clear.In the test sample chromatograph, with control medicinal material and the corresponding position of reference substance chromatograph on, show the speckle of same color.
[inspection] should meet each item regulation (an appendix I of Chinese Pharmacopoeia version in 2010 C) relevant under the granule item.
[assay] measured according to HPLC (an appendix VI of Chinese Pharmacopoeia version in 2010 D).
Chromatographic condition and system suitability test use octadecylsilane chemically bonded silica to be filler; Methanol-water (25:75) is a mobile phase; The detection wavelength is 250nm.Number of theoretical plate calculates by puerarin peak should be not less than 4000.
It is an amount of that the puerarin reference substance of drying under reduced pressure to constant weight is got in the preparation of reference substance solution, adds water and process the solution that every 1ml contains 30 μ g, promptly gets.
The about 0.1g of these article is got in the preparation of need testing solution, and accurate the title decides, and puts in the 25ml measuring bottle, adds water 20ml supersound process (power 300W; Frequency 25KHz) after 20 minutes, cooling, water is settled to scale; Filter with microporous filter membrane (0.45 μ m), get subsequent filtrate, promptly get.
Accurate respectively reference substance solution and each the 20 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, and promptly get.
These article contain Radix Puerariae in puerarin for every bag, must not be less than 29.0mg.
Chinese medicine granules of the present invention and former XINKESHU JIAONANG clinical efficacy are relatively
Case is selected: meet diagnostic criteria patient totally 125 examples, the Chinese medicine granules of establishing invention is the treatment group, and former XINKESHU JIAONANG is a matched group.68 examples are organized in treatment, wherein male 58 examples, women 10 examples, 51 years old mean age.Matched group 57 examples, wherein male 50 examples, women 7 examples, 49 years old mean age.
One, treatment hyperlipidemia
1, diagnostic criteria
Being diagnosed as of latest domestic dyslipidemia: blood fat project [mg/dl (mmol/L)]
(1) T-CHOL TC: OK range<200 (<5.17), edge rising 200-239 (5.17-6.21)>=240 (>=6.21) that raise
(2) low-density lipoprotein cholesterol LDL-C: OK range<130 (<3.36) edge rising 130-159 (3.36-4.14)>=160 (>=4.14) that raise
(3) HDL-C HDL-C: reduce by 40 (1.03)
(4) triglyceride TG: OK range 150 (1.69) edge rising 150 ~ 199 (1.69-2.26) rising >=200 (>=2.26)
2, curative effect determinate standard TCH descends >=20%, and TG descends >=40%, and HDL-C rising >=0.26mmol/L is a produce effects; TCH descends and reaches 10-20%, and TG descends and reaches 20-40%, and HDL rising >=0.18mmol/L is effective; It is invalid not reaching effective standard, and TCH rises >=10%, and TG rises >=10%, and HDL-C descends and reaches 0.18mmol/L for worsening.
Two, treatment myocardial ischemia
1, inclusion criteria 24 hr Ambulatory EKG Monitoring have the T ripple, the ST-T changer (the ST section moves down >=0.1mV), except merge serious hypertension, diabetes, pulmonary insufficiency and other severe cardiac disorder person.
2, check 24 hr Ambulatory EKG Monitoring after all cases of efficacy assessment standard are taken medicine.(1) produce effects: ischemic ST-T disappears, and clinical symptoms disappears basically; (2) effective: the ischemic ST-T frequency of occurrences reduce 50% or the ST section go up >=O.05mV but the deviant improve but clinical symptoms is most of; (3) invalid: 24 hr Ambulatory EKG Monitoring no changes, clinical symptoms is improved not obvious.
Three, the curative effect to treatment hyperlipidemia and treatment myocardial ischemia compares
Can find out from last table, treatment hyperlipidemia 45 examples, treatment group total effective rate is 88.89%, the matched group total effective rate is 62.22%; Treatment myocardial ischemia 60 examples, treatment group total effective rate is 85.00%, and the matched group total effective rate is 60.00%, and Chinese medicine granules of the present invention has better therapeutic than matched group.
Claims (2)
1. the Chinese medicine composition of a blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain; It is characterized in that, process: Fructus Crataegi 7.5-22.5 part, Radix Salviae Miltiorrhizae 7.5-22.5 part, Radix Puerariae 7.5-22.5 part, Radix Notoginseng 1-3 part, Radix Aucklandiae 1-3 part, dextrin 7.5-22.5 part, stevioside 0.25-0.75 part by following parts by weight of Chinese traditional medicine crude drug and adjuvant;
The process for producing granula of said blood circulation promoting and blood stasis dispelling promoting the circulation of QI to relieve pain Chinese medicine composition may further comprise the steps: Radix Notoginseng, the Radix Aucklandiae are ground into 150-250 purpose fine powder with the micropowder pulverizer, and subsequent use; Fructus Crataegi, Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into 50-70 order powder, adopt its effective active composition of supercritical carbon dioxide extraction method extraction, the extraction process condition is following: extracting pressure 34-36MPa, extraction temperature 48-52 ℃; 110-130 minute extraction time, separator pressure 9.0-11.0MPa, separator temperature 39-41 ℃, carbon dioxide flow is 78-82L/H; Extraction finishes, and system pressure is reduced to normal pressure, and extract is separated out separation, gets extractum; With extract dry, again extract powder is broken into 150-250 order fine powder then, with Radix Notoginseng, Radix Aucklandiae fine powder and dextrin, stevioside mixing; Process granule, packing.
2. the Chinese medicine composition of blood circulation promoting and blood stasis dispelling promoting the circulation of QI to relieve pain according to claim 1; It is characterized in that, process: 15 parts of Fructus Crataegis, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Puerariaes, 2 parts of Radix Notoginseng, 2 parts of the Radix Aucklandiae, 15 parts in dextrin, 0.5 part of stevioside by following parts by weight of Chinese traditional medicine crude drug and adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101411337A CN102210763B (en) | 2011-05-30 | 2011-05-30 | Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101411337A CN102210763B (en) | 2011-05-30 | 2011-05-30 | Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102210763A CN102210763A (en) | 2011-10-12 |
| CN102210763B true CN102210763B (en) | 2012-08-22 |
Family
ID=44742447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101411337A Active CN102210763B (en) | 2011-05-30 | 2011-05-30 | Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210763B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114414723B (en) * | 2022-01-21 | 2023-05-30 | 北京大学 | Thin-layer full-medicine taste identification method for Xinkeshu tablets |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883587A (en) * | 2006-05-19 | 2006-12-27 | 山东沃华医药科技股份有限公司 | Preparation of 'Xin Ke Shu' tablet for treating coronary heart disease |
-
2011
- 2011-05-30 CN CN2011101411337A patent/CN102210763B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883587A (en) * | 2006-05-19 | 2006-12-27 | 山东沃华医药科技股份有限公司 | Preparation of 'Xin Ke Shu' tablet for treating coronary heart disease |
Non-Patent Citations (1)
| Title |
|---|
| 梁绪国等.心可舒片对血管内皮细胞凋亡及凋亡调控基因的影响.《中华中医药学刊》.2008,第26卷(第5期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102210763A (en) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| WO2011113190A1 (en) | Pharmaceutical composition for treating aids and preparation method thereof | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN103705594A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN103655791B (en) | A kind of lotus leaf-based preparation for treating phlegm and blood stasis simultaneously and application thereof | |
| CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
| CN108704007A (en) | A kind of preparation method of Radix Polygalae active ingredient | |
| CN102210763B (en) | Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof | |
| CN101940642A (en) | Chinese medicinal composition and application thereof | |
| Koo et al. | Extraction of hypotensive principles from seeds of Cassia tora | |
| CN101125154B (en) | Raidx cynanchum bungei decne glycoside of mountain Tai and preparation method thereof | |
| CN101513432A (en) | Preparation and new usage of selaginella tamariscina biflavone ingredient | |
| CN116098970A (en) | Preparation method of Mailuo Shutong extract | |
| CN104547026B (en) | Preparation method and application of salvia miltiorrhiza leave pseudo-ginseng extract | |
| CN102743646A (en) | Medicinal composition for inspecting and preventing diabetes | |
| CN102755450A (en) | Preparation method of anti-inflammation detoxifying traditional Chinese medicine composition | |
| CN101461877B (en) | Medicament composition for recovery of physical strength for women | |
| CN105381402A (en) | Qi-regulating and heart-soothing tablet and preparation method thereof | |
| CN101919919A (en) | Fukean dispersible tablet and preparation method thereof | |
| CN110585295A (en) | Compound itching-relieving granule and preparation method thereof | |
| CN104547027B (en) | Preparation method and application of salvia miltiorrhiza leave and panax notoginseng leaf extract | |
| CN103690834B (en) | A kind of blood pressure lowering Chinese medicinal composition and preparation method thereof | |
| CN102558249A (en) | Salvia miltiorrhiza stachyose, and preparation method and application thereof | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicinal composition for promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain and preparation method thereof Effective date of registration: 20181225 Granted publication date: 20120822 Pledgee: Yongzhou Rural Commercial Bank Co.,Ltd. Pledgor: HUNAN HENGWEI PHARMACEUTICAL Co.,Ltd. Registration number: 2018990001258 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200615 Granted publication date: 20120822 Pledgee: Yongzhou Rural Commercial Bank Co.,Ltd. Pledgor: HUNAN HENGWEI PHARMACEUTICAL Co.,Ltd. Registration number: 2018990001258 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a traditional Chinese medicine composition for promoting blood circulation and removing blood stasis, promoting qi and relieving pain and a preparation method thereof Effective date of registration: 20211129 Granted publication date: 20120822 Pledgee: Bank of Changsha Co.,Ltd. Yongzhou branch Pledgor: HUNAN HENGWEI PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980013474 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20120822 Pledgee: Bank of Changsha Co.,Ltd. Yongzhou branch Pledgor: HUNAN HENGWEI PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980013474 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of traditional Chinese medicine composition for promoting blood circulation and removing blood stasis, promoting qi and relieving pain and preparation method thereof Effective date of registration: 20220921 Granted publication date: 20120822 Pledgee: Bank of Changsha Co.,Ltd. Yongzhou branch Pledgor: HUNAN HENGWEI PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980015866 |